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Abstract 
Background: The aim of this study was to examine sexual function and its correlates among infertile women with 
polycystic ovary syndrome (PCOS) in comparison with their non-PCOS counterparts.
Materials and Methods: In this case-control study, 209 infertile women (116 PCOS and 93 non-PCOS) from Tehran, 
Iran, were evaluated in February and March 2018. Female sexual function index (FSFI), hormonal status, and docu-
mented reports of hyperandrogenic manifestations of the patients were investigated.
Results: The mean age of the patients was 32.00 ± 5.00 years old. Eighty-four (40.2%) patients including 42.2% of 
the PCOS patients and 37.6% of the non-PCOS cases (P>0.05), were suspected of female sexual dysfunction (FSD). 
The most impaired functions in both groups were desire and arousal. Sexual function was not significantly different 
between the groups. However, PCOS women had more orgasm problems and acne worsened their sexual function. To-
tal FSFI was positively associated with prolactin level but negatively associated with central obesity in the non-PCOS 
group; it was negatively correlated with marital duration in the PCOS group. Luteinizing hormone (LH) and pain, pro-
lactin level and lubrication, and central obesity and arousal were correlated in the non-PCOS women. Prolactin level 
and orgasm, marital duration and arousal, and marital duration and the total FSFI were correlated in the PCOS women.
Conclusion: Sexual function was similarly low in infertile PCOS and non-PCOS women. However, orgasm problems 
and the negative effect of acne varied between the two groups. Further investigations may target how hormonal profile 
may affect sexual function. Practitioners should scrutinize the specific impaired sexual domains and their correlated 
conditions in PCOS women, notably orgasm, acne, and prolactin level. Interventions should be well tailored based on 
particular needs of infertile PCOS women.
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Introduction
Infertility is a disease of the reproductive system that is 
defined as “the failure to achieve a clinical pregnancy af-
ter 12 months or more of regular unprotected sexual inter-
course” (1). In the Iranian population, recent estimations 
indicated that lifetime primary infertility rates, based on 
clinical, epidemiological, and demographic definitions 
set by the World Health Organization, are respectively 
20.2, 12.8, and 9.2%, while that of secondary infertility is 
4.9% (2). One of the common disorders linked to infertil-
ity and associated with ovulation problems is polycystic 
ovary syndrome (PCOS). The definition of PCOS by the 
United States National Institutes of Health entails anovu-
lation and hyperandrogenemia. However, the European 
Society of Human Reproduction and Embryology/Ameri-
can Society for Reproductive Medicine (ESHRE/ASRM) 
defines PCOS as polycystic ovaries diagnosed based on 
ultrasound (3). Studies have reported that up to 83% of 
infertile Iranian women have PCOS, and an infertility rate 
of 8-73% in PCOS patients was shown (4).
Sexual life of infertile women is a pivotal research area 
because infertility is associated with an increased risk of 
female sexual dysfunction (FSD) (5). Sexual function in-
volves various domains, including sexual desire, arousal, 
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vaginal lubrication, experiencing orgasm, coital satisfac-
tion, and feeling of pain during intercourse (6). Infertile 
couples are more prone to develop sexual dysfunction. A 
recent estimation in infertile Iranian women, for instance, 
found that 64.3% of the patients developed sexual dys-
function, with sexual desire and vaginismus having the 
highest and lowest rates, respectively (7). Another study 
suggested that the sexual behavior of infertile Iranian 
women is severely narrowed to produce pregnancy (8) 
and that infertility causes Iranian women to suffer from 
serious problems in various domains, including sexuality 
(9). More to the point, sexual dysfunction may consid-
erably affect mental health as well as the sexual quality 
of life (10). Furthermore, women’s sexual problems may 
even escalate if they concurrently suffer from PCOS (11). 
That is, the sexuality of women with PCOS may become 
even more compromised, especially as a result of obe-
sity, hirsutism, baldness, and acne (12). Moreover, sexual 
problems are suggested as the possible causes of discrep-
ancies in perceptions of infertile women with and without 
PCOS towards their sexual life and function (13).
Although various studies have addressed the sexual 
problems experienced by women with PCOS (14, 15), 
few studies have focused on sexual issues and their cor-
relates when such patients simultaneously suffer from 
infertility. Recent meta-analyses have determined similar 
sexual function between PCOS women and healthy con-
trols (16, 17). However, it can be argued that further stud-
ies investigating possible effects of comorbid PCOS and 
infertility are warranted, especially in the Iranian popula-
tion. Moreover, investigating possible differences in sex-
ual problems and their correlates between infertile PCOS 
patients and their non-PCOS counterparts may provide 
more knowledge about the specific role that comorbid 
PCOS and infertility play in Iranian women life.
The present study, therefore, investigated the differ-
ences between infertile Iranian women with and without 
PCOS in terms of sexual function. It also aimed to evalu-
ate the degree to which hormonal, anthropomorphic, and 
hyperandrogenic manifestations may be correlated with 
the sexual function of these groups of women.
Materials and Methods
Study design and sampling
This case-control study involved infertile PCOS women 
as the case group and their infertile non-PCOS counter-
parts as the control group using a convenience sampling 
method. Patients visiting two infertility centers in Teh-
ran, Iran were recruited. The study was introduced and 
explained to the patients to obtain their informed con-
sent. The questionnaires were administered using the 
interviewer-administered method. Overall, 216 infertile 
women were recruited in February and March of 2018. 
The sample size was determined for two independent 
samples using G*Power software V.3 (18). The estima-
tion setting was set to a medium effect size (0.50), a sig-
nificance level (α) of 0.05 (two-tailed), a power of 0.80, 
and an allocation ratio of 1. The calculation suggested 
that a sample size of 128 participants (64 for each group) 
could achieve the actual power of 0.803. The inclusion 
criteria were as follows: age above 18 years and diagnosis 
of infertility for both groups, and diagnosis of PCOS for 
the PCOS group. PCOS was diagnosed based on the inter-
national evidence-based guideline for the assessment and 
management of PCOS, 2018 (19). This guideline identi-
fies the condition in adult women if two of the three con-
ditions of androgen excess, ovulatory dysfunction, and 
polycystic ovarian morphology are present. Ultrasound is 
required if either androgen excess or ovulatory dysfunc-
tion is not present. Certain disorders, including thyroid 
disease (based on thyroid-stimulating hormone (TSH) 
level), hyperprolactinemia (based on prolactin level), 
and non-classic congenital adrenal hyperplasia (based on 
17-hydroxyprogesterone (17-OHP) level), were ruled out 
by clinical judgment.
The following exclusion criteria were considered: psychi-
atric disorders; severe emotional problems in the past six 
months; consumption of oral contraceptive pills, gonadotro-
pin-releasing hormone (GnRH) agonists, or insulin sensitiz-
ers in the past six months; chronic cardiovascular diseases; 
primary or secondary vaginismus and dyspareunia; pelvic 
mass; active genital infection; external vaginal anomalies; 
pelvic endometriosis; and partner’s sexual dysfunction.
Measures
A checklist was devised to survey the participants’ de-
mographic information, including the patient’s age, oc-
cupation, and education, the spouse’s age and education, 
and the duration of their marriage. Clinical information in-
cluding duration of infertility, duration of treatment, cen-
tral obesity (waist-to-hip ratio), body mass index (BMI), 
and hyperandrogenic manifestations, including the pres-
ence of acne, hirsutism (Ferriman-Gallwey score), and 
baldness (i.e. male-pattern hair loss), was also collected. 
On the third day of the menstrual cycle (induced by 
100-200 mg progesterone in oil injection in amenorrhe-
ic patients), a baseline vaginal ultrasound examination 
was performed, and serum follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), TSH, and prolactin 
levels were measured using immunoradiometric assays 
(Izotop, Budapest, Hungary). Dehydroepiandrosterone 
sulfate (DHEAS), 17-OHP, and total testosterone (TT) 
were measured using enzyme immunoassays (Diagnos-
tics Biochem Canada Inc., London, Canada). 
The Female Sexual Function Index (FSFI) (20) was em-
ployed to assess the patients’ sexual function. This 19-item 
questionnaire assesses six domains of sexual desire (two 
items, domain factor 0.6), arousal (four items, domain fac-
tor 0.3), lubrication (four items, domain factor 0.3), orgasm 
(three items, domain factor 0.4), satisfaction (four items, 
domain factor 0.4), and pain (three items, domain factor 
0.4) for a comprehensive evaluation of the female sexual 
response cycle. Each domain’s raw score is multiplied by 
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its domain factor, yielding a possible score in the range of 
0 to 6, except for desire, which has a range of 1.2 to 6. 
According to the score which ranges 1.2-36, higher total 
scores indicate better sexual function. The questionnaire 
can identify women who had no sexual encounters during 
the preceding four weeks. The Persian version of the FSFI 
was approved as a valid and reliable screening and assess-
ment instrument, indicating a Cronbach’s alpha of 0.93 and 
test-retest reliability of 0.83 (21). The instrument showed 
a Cronbach’s alpha of 0.89 in the current dataset. The sec-
ond and fifth authors administered the questionnaires using 
the interviewer-administered method by asking patients to 
choose the response that best described their status.
FSD was identified based on FSFI scores. In an original 
study by Rosen, scores lower than 26.55 indicated a diag-
nosis of FSD with a specificity of 0.73 and a sensitivity 
of 0.89 (20). In addition, a raw score below 3.9 indicated 
sexual dysfunction in each domain (22). 
Ethical considerations
This study was performed according to the Declaration 
of Helsinki, and the Ethics Committee of Iran University 
of Medical Sciences approved the study protocol (ID: 
IR.IUMS.FMD.REC.1396.9311290023). Informed con-
sent was obtained from all participants.
Statistical analysis 
Statistical analysis was performed using IBM SPSS Sta-
tistics for Windows, Version 24.0 (IBM Corp., Armonk, 
NY, USA) (23). Missing data were handled using the 
pairwise deletion method. Since the scores showed a non-
normal distribution, non-parametric statistics was adopt-
ed. The Mann-Whitney U test and the Chi-square test for 
comparing the groups, as well as logistic regression for 
predicting FSD via hyperandrogenic manifestations, were 
conducted. Spearman’s Rho was also calculated to deter-
mine the correlation of patient’s age, duration of infertil-
ity, duration of treatment, BMI, central obesity, levels of 
FSH, TSH, LH, prolactin, TT, DHEAS, and 17-OHP (all 
in mcg/L), and LH/FSH ratio with the total FSFI score 
and the domains. Two-tailed P value was set at <0.05.
Results
Sample characteristics
Among the 216 patients recruited in this study, seven 
(0.03%) patients were sexually inactive based on the FSFI 
and were excluded. Therefore, 209 infertile women, in-
cluding 116 PCOS patients and 93 non-PCOS patients, 
remained in the study.
Table 1 presents the demographic and clinical char-
acteristics of the patients. The mean age was 32.00 ± 
5.00 years, with the PCOS group being older (P<0.001). 
Central obesity was more frequent in the PCOS group 
(P<0.01), and there was a higher degree of anovulation 
as the cause of infertility (P<0.001) in this group. Con-
versely, infertility in the non-PCOS group was more often 
found to be unexplained or due to tubal causes (P<0.01).
Evaluation of female sexual function
Table 2 presents the sexuality domains for both groups. 
Arousal had the lowest score in the PCOS group (3.69 ± 
1.23) and non-PCOS group (3.67 ± 1.32). On the other 
hand, the highest mean score was related to satisfaction 
in the PCOS group (5.06 ± 1.00) and non-PCOS group 
(5.11 ± 0.95). The total FSFI for in our sample population 
was 27.15 ± 4.30, with 26.97 ± 4.73 in the PCOS group 
and 27.38 ± 3.72 in the non-PCOS group. FSD was diag-
nosed in 40.2% of the participants, including 42.2% of 
the PCOS patients and 37.6% of the non-PCOS patients.
Sexual function comparison
Table 3 presents comparisons between the PCOS and non-
PCOS groups in terms of sexual function. Based on the raw 
scores for sexual function, there were no significant differ-
ences between the two groups (P=0.325 to 0.975). Also, the 
two groups had no significant difference in terms of FSD 
(P=0.500). Based on the categorization of sexual dysfunc-
tion in the domains (score<3.9), the two groups only showed 
a significant difference in orgasm problems (P=0.035).
Hyperandrogenic manifestations and sexual function
According to Table 3, acne (51.7%), baldness (41.4%), 
and hirsutism (57.8%) were more commonly found in the 
infertile PCOS patients (P<0.001). Acne was the sole im-
pactful hyperandrogenic manifestation, increasing the odds 
of FSD by 1.87 [1.02, 3.43] (P=0.042) in the total sample 
and 2.18 [1.01, 4.68] (P=0.046) in the PCOS group.
Hormone comparison
Table 4 presents the results of the hormone tests in both 
groups. Group differences were seen in FSH, which was 
higher in the non-PCOS group, and LH, which was higher in 
the PCOS group (P<0.001). The LH/FSH ratio was higher in 
the PCOS group to a statistically significant degree (P<0.001).
Sexual function correlates
In the non-PCOS patients, there were significant rela-
tionships between LH and pain (n=87, rho=0.26, P=0.015), 
prolactin level and lubrication (n=85, rho=0.22, P=0.048), 
prolactin level and total FSFI (n=85, rho=0.22, P=0.045), 
and central obesity and arousal (n=93, rho=-0.26, P=0.013). 
In the PCOS group, marital duration and arousal (n=103, 
rho=-0.31, P=0.001), marital duration and total FSFI 
(n=103, rho=-0.25, P=0.013), and prolactin level and or-
gasm (n=114, rho=-0.23, P=0.012) were correlated.
Confounding effect of age
Because the mean ages of the two groups were statisti-
cally significantly different (P<0.001, Table 1), the analy-
ses were repeated using linear regression analysis, includ-
ing the PCOS group as the dummy variable and age as 
the covariate. There were no significant changes in the 
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Test statistic P value
Patient’s age (Y) 32.00 ± 5.00 31.00 ± 5.00 34.00 ± 6.00 z=-4.06 <0.001a
Spouse’s age (Y) 36.00 ± 6.00 35.00 ± 6.00 37.00 ± 6.00 z=-3.57 <0.001a
Duration of marriage (Y) 6.70 ± 4.40 6.40 ± 4.20 7.10 ± 4.70 z=0.96 0.339a
Duration of infertility (Y) 4.20 ± 3.40 4.00 ± 3.50 4.40 ± 3.40 z=-1.50 0.133a
Duration of treatment (Y) 0.80 ± 0.61 0.79 ± 0.64 0.82 ± 0.58 z=0.98 0.329a
BMI 26.63 ± 4.10 26.66 ± 3.85 26.58 ± 4.43 z=0.76 0.448a
Central obesity 0.90 ± 0.06 0.91 ± 0.06 0.89 ± 0.06 z=2.61 0.009a
Patients’ education
   Illiterate 4 (1.9) 2 (1.7) 2 (2.2) χ2[5] = 8.33 0.139b
   Primary 13 (6.2) 6 (5.2) 7 (7.5)
   Secondary 29 (13.9) 20 (17.2) 9 (9.7)
   Diploma 74 (35.4) 40 (34.5) 34 (36.6)
   University 53 (25.4) 34 (29.3) 19 (20.4)
   Missing data 36 (17.2) 14 (12.1) 22 (23.7)
Patients’ job
   Housewife 149 (71.3) 85 (73.3) 64 (68.8)  χ2[3] =5.00 0.172b
   Home-based 2 (1.0) 2 (1.7) 0 (0.0)
   Employed 26 (12.4) 16 (13.8) 10 (10.8)
   Missing data 32 (15.3) 13 (11.2) 19 (20.4)
Spouses’ education
   Illiterate 4 (1.9) 3 (2.6) 1 (1.1) χ2[5] = 9.12 0.104b
   Primary 14 (6.7) 7 (6.0) 7 (7.5)
   Secondary 45 (21.5) 27 (23.3) 18 (19.4)
   Diploma 65 (31.1) 36 (31.0) 29 (31.2)
   University 41 (19.6) 28 (24.1) 13 (14.0)
   Missing data 40 (19.1) 15 (12.9) 25 (26.9)
Infertility type
   Primary 125 (59.8) 75 (64.7) 50 (53.9) χ2[2] = 2.95 0.229b
   Secondary 63 (30.1) 31 (26.7) 31 (33.3)
   Missing data 21 (10.0) 9 (7.8) 12 (12.9)
Previous treatment
   None 51 (24.4) 33 (28.4) 18 (19.4) χ2[1] = 3.57 0.168b
   Induce 65 (40.4) 44 (46.8) 21 (31.3) χ2[1] = 3.89 0.049b
   IUI 65 (40.4) 32 (34.0) 33 (49.3) χ2[1] = 3.76 0.052b
   IVF/ICSI 29 (18.0) 15 (16.0) 14 (20.9) χ2[1] = 0.65 0.442b
   Missing data 48 (23.0) 22 (19.0) 26 (28.0)
Infertility causec
   Anovulation 128 (61.2) 110 (94.8) 18 (19.4) χ2[1] = 123.87 <0.001b
   Tubal 26 (12.4) 6 (6.0) 19 (20.4) χ2[1] = 9.82 0.002b
   Unexplained 17 (8.1) 3 (2.6) 14 (15.1) χ2[1] = 10.73 0.001b
   Missing data 42 (20.1) 0 (0.0) 42 (45.2)
Data are presented as mean ± SD or n (%). IUI; Intrauterine insemination, IVF; In vitro fertilization, ICSI; Intrauterine insemination, PCOS: Polycystic ovary syndrome, BMI; Body mass index, 
a; Mann-Whitney U (Asymp. P), b; Pearson’s Chi-square test (2-sided), and c; Anovulation and tubal categories are not mutually exclusive. The bolded P indicates a significant difference. 
pattern of the comparisons. Additionally, controlling for 
age, partial correlations were estimated between each pair 
of hormones and sexuality domains. Consequently, the re-
sults indicated only negligible changes to the zero-order 
correlations. Therefore, the previously reported differ-
ences and correlations were shown to be valid.
Sexual Function in PCOS
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tic Pa χ2[1] Pb
M ± SD Min, Max FSD n (%) M ± SD Min, Max
FSD
n (%) M ± SD Min, Max
FSD 
n (%)
Desire 3.79 ± 1.05 1.20, 6.00 117 (56.0) 3.78 ± 1.01 1.20, 6.00 67 (57.8) 3.81 ± 1.09 1.20, 6.00 50 (53.8) -0.24 0.792 0.33 0.563
Arousal 3.68 ± 1.27 1.20, 6.00 91 (43.5) 3.69 ± 1.23 1.20, 6.00 56 (48.3) 3.67 ± 1.32 1.20, 6.00 35 (37.6) -0.29 0.775 2.38 0.123
Lubrication 4.99 ± 1.12 1.20, 6.00 34 (16.3)   4.92 ± 1.15 1.20, 6.00 21 (18.1) 5.07 ± 1.07 1.20, 6.00 13 (14.0) -0.99 0.325 0.65 0.442
Orgasm 4.60 ± 1.08 1.20, 6.00 48 (23.0) 4.52 ± 1.17 1.20, 6.00 33 (28.4) 4.68 ± 0.95 1.20, 6.00 15 (16.1) -0.61 0.539 4.43 0.035
Satisfaction 5.08 ± 0.98 2.40, 6.00 26 (12.4) 5.06 ± 1.00 2.40, 6.00 15 (12.9) 5.11 ± 0.95 2.40, 6.00 11 (11.8) -0.34 0.738 0.06 0.810
Pain 5.01 ± 1.05 1.60, 6.00 34 (16.3)   5.00 ± 1.09 1.60, 6.00 22 (19.0)  5.04 ± 1.00 1.60, 6.00 12 (12.9) -0.03 0.978 1.39 0.238
FSFI 27.15± 4.30 15.90, 36.00 84 (40.2) 26.97 ± 4.73 15.90, 36.00 49 (42.2) 27.38 ± 3.72 16.60, 34.50 35 (37.6) -0.29 0.774 0.46 0.500
PCOS; Polycystic ovary syndrome, M; Mean, SD; Standard deviation, Min; Minimum, Max; Maximum, FSFI; Female sexual function index, FSD; Female sexual dysfunction (FSFI below 26.55 
for global FSD and below 3.9 for domain FSD), a; Mann-Whitney U (Asymp. P) on the raw scores, and b; Pearson’s Chi-square test (2-sided) on the FSD categorizations. The bolded P indicates 
a significant difference.








Unadjusteda Adjustedb Unadjusteda Adjustedb
n (%) Odds [95%CI]
Acne 
None 135 (64.6) 54 (46.6) 81 (87.1) 1.87 [1.02, 3.43] 2.15 [1.12, 4.11] 2.18 [1.01, 4.68] 2.22 [1.00, 4.89]
Mild 48 (23.0) 44 (37.9) 4 (4.3)
Moderate 13 (6.2) 13 (11.2) 0 (0.0)
Severe 3 (1.4) 3 (2.6) 0 (0.0)
Baldness 
None 151 (72.2) 66 (56.9) 85 (91.4) 0.89 [0.45, 1.73] 0.77 [0.38, 1.56] 0.77 [0.36, 1.64] 0.62 [0.28, 1.27]
Mild 28 (13.4) 28 (24.1) 0 (0.0)
Moderate 14 (6.7) 14 (12.1) 0 (0.0)
Severe 6 (2.9) 6 (5.2) 0 (0.0)
Hirsutism 
None 129 (61.7) 47 (40.5) 82 (88.2) 1.34 [0.74, 2.42] 1.44 [0.77, 2.71] 1.23 [0.57, 2.63] 1.22 [0.56, 2.67]
Mild 44 (21.1) 41 (35.3) 3 (3.2)
Moderate 18 (8.6) 18 (15.5) 0 (0.0)
Severe 8 (3.8) 8 (6.9) 0 (0.0)
FSFI; Female sexual function index, FSD; Female sexual dysfunction (FSFI below 26.55), PCOS; Polycystic ovary syndrome, CI; Confidence interval, a; The unadjusted models included each 
hyperandrogenic manifestation as an independent variable and FSD as a dependent variable, and b; The models were adjusted for age. Bolded results indicate significant (P<0.05).
Table 4: Comparisons of laboratory results







n M ± SD Min, Max n M ± SD Min, Max n M ± SD Min, Max
FSH 201 4.93 ± 3.27 0.50, 24.00 110 4.14 ± 2.34 1.30, 18.10 91 5.97 ± 3.96 0.50, 24.00 -4.73 <0.001
TSH 202 1.98 ± 1.07 0.09, 7.00 111 1.95 ± 0.96 0.20, 6.20 91 2.01 ± 1.19 0.09, 7.00 0.19 0.848
LH 201 5.75 ± 4.39 0.05, 42.30 111 6.77 ± 4.96 0.70, 42.30 91 4.40 ± 3.05 0.05, 16.10 5.13 <0.001
Prolactin 199 14.57 ± 7.79 1.00, 61.10 109 14.30 ± 5.42 2.30, 35.80 91 14.93 ± 10.17 1.00, 61.10 0.80 0.427
Testosterone 141 1.69 ± 0.73 0.40, 3.80 93 1.79 ± 0.83 0.40, 3.80 46 1.60 ± 0.60 0.40, 3.10 1.44 0.150
DHEAS 117 1.72 ± 0.85 0.30, 5.80 80 1.87 ± 1.07 0.40, 5.80 37 1.55 ± 0.48 0.30, 2.70 0.85 0.395
17-OHP 120 2.0 ± 0.68 0.40, 4.00 80 1.93 ± 0.63 0.40, 3.50 40 2.07 ± 0.73 0.50, 4.00 -0.91 0.364
LH/FSH 201 1.41 ± 0.97 0.02, 5.19 87 1.78 ± 0.95 0.22, 5.19 114 0.91 ± 0.74 0.02, 3.73 7.11 <0.001
PCOS; Polycystic ovary syndrome, M; Mean, SD; Standard deviation, Min; Minimum, Max; Maximum, FSH; Follicle-stimulating hormone, TSH; Thyroid-stimulating hormone, LH; Luteinizing 
hormone, DHEAS; Dehydroepiandrosterone sulfate and 17-OHP: 17-hydroxyprogesterone, a; All values are in microgram per liter, and b; Mann-Whitney U (Asymp. P). Bolded results indicate 
a significant difference. 
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Discussion
The aim of this study was to evaluate sexual function 
and its correlates among infertile patients with and without 
PCOS. The findings suggest that infertile women with and 
without PCOS considerably suffered from diminished 
sexual function. A recent meta-analysis reported domains 
of lubrication, orgasm, and satisfaction to be the sources 
of difference between infertile and fertile women (24), 
while these three domains were proportionately better in 
the two groups evaluated in the current study.
It should be noted that domain-specific FSD was 
determined by a relatively higher cut-off point (< 3.9), 
which was originally applied to infertile women (25); 
however, some other studies employing slightly lower 
cut-off points, reported a relatively higher degree of 
domain-specific FSD in healthy Iranian women (26). 
Nevertheless, similar to the aforementioned study (26), 
desire and arousal problems not only showed a marked 
prevalence but were also the most problematic sexual 
domains in the current study.
In addition, the literature suggests that women with 
and without PCOS in the general population (16, 17) and 
infertile Iranian women with and without PCOS (27) do 
not differ in terms of sexual function. Although PCOS 
women compared with their healthy counterparts, may 
mainly have dissatisfaction with their sex life, rather than 
with sexual activity (28), the current study indicated a 
diminished level of sexual function in both groups, with 
the orgasm domain being a specific source of difference. 
This indicates a crucial need for further attention paid to 
the sexuality of infertile PCOS women.
Furthermore, while some studies could not determine 
the effects of hyperandrogenic manifestations on sexual 
function (29), others indicated that acne-related concerns 
could reduce sexual satisfaction in both PCOS women and 
their spouses (30). Also, in our study, although infertile 
PCOS patients featured higher levels of LH and FSH, as 
well as an elevated LH/FSH ratio, it was the non-PCOS 
group that showed a significant association between LH 
and pain. In addition, an earlier study found no association 
between LH and quality of life of PCOS patients (31). 
However, LH was previously shown to be connected with 
orgasm problems in healthy, postmenopausal women 
(32) and with sexual function in PCOS patients in the 
general population (33). LH contributes to the circulation 
of reproductive hormones, including androgens and 
estrogens (34), and it is suggested to make women apt 
to love and intimacy (35). In addition, studies in which 
significant hormonal correlations were seen with LH in 
PCOS patients, emphasized the multifactorial nature of 
human sexual function which can be influenced by a 
variety of psychosocial and cultural factors (33). Thus, 
more studies are needed to provide supports for the results 
observed in the current study.
The current study revealed a significant contrast between 
the two groups in the relationship between prolactin level 
and sexual function. Other studies have also reported 
that among various relevant hormones, there was only a 
negative association between prolactin level and function 
of orgasm in PCOS women (36). Elevated prolactin levels 
were found to be associated with sexual problems in the 
general population (37). Also, women with PCOS can have 
mildly elevated levels of prolactin (38). Thus, the current 
results in line with the previous findings (36), indicated 
the diminished function of orgasm to be associated with 
higher prolactin levels in infertile PCOS women.
Contrary to expectations, higher central obesity which is 
marked in PCOS women (11, 12), indicated lower sexual 
arousal in infertile non-PCOS women only. Additionally, 
although some studies reported that the age of infertile 
women had a negative association with sexual function 
(39), the current findings instead, suggest the negative 
impact of marital duration on sexual arousal and total 
FSFI in infertile PCOS women. Thus, the current results 
indicate that obesity and marital characteristics could 
also be sources of difference in sexual function between 
infertile PCOS women and those without PCOS. 
Ultimately, the distinctions raised in the current study 
suggest that infertile PCOS and non-PCOS women 
may need more well-tailored research on their specific 
biological, hormonal, and psychological dimensions. It is 
suggested that future studies include spouses assessments 
to further examine the relational nature of sexual desire 
and arousal in patients. More importantly, some studies 
have suggested implementing educational interventions to 
enhance the sexual function of infertile women (40). The 
current study, which indicates the exclusively negative 
effect of prolactin level, acne, and marital duration on 
the sexual function of infertile PCOS women, implies 
that interventions may need to be modified accordingly 
to educate patients on how to manage their specific 
problems. Last but not least, policymakers concerned 
with the family structure and sexual health of the Iranian 
population, should focus on and facilitate particular needs 
and problems of the patients in order to maintain their 
marriage as socially stable and psychologically fruitful as 
the wider population does.
This study lacked a control group of fertile women. 
Therefore, it failed to find any possible differences 
between fertile and infertile women, especially those who 
may seek professional help for their sexual problems. 
Moreover, since this study had a cross-sectional design, 
caution needs to be taken in making any generalizations 
or considering causal implications.
Conclusion
This study demonstrated diminished sexual function in 
infertile Iranian women, especially in terms of the desire 
and arousal domains. The PCOS and non-PCOS groups 
were not significantly different in terms of sexual function, 
while orgasm dysfunction was higher in the PCOS 
women. In addition, acne increased sexual dysfunction 
in the PCOS women. The infertile non-PCOS women 
Sexual Function in PCOS
Int J Fertil Steril, Vol 15, No 1, January-March 202171
with higher levels of prolactin had lower dyspareunia and 
those with higher LH had lower total FSFI and lubrication 
problems, while the higher the central obesity the higher 
their arousal problems. However, infertile PCOS women 
mainly showed orgasm dysfunction as a result of lower 
levels of prolactin, and lower total FSFI and arousal as a 
result of marital duration.
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